Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Next Previous
Search
Trial Profile

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Erythrodermic psoriasis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Focus Therapeutic Use
  • Acronyms BE CARING
  • Sponsors UCB Biopharma

Most Recent Events

  • 30 Apr 2025 Planned initiation date changed from 7 Apr 2025 to 16 May 2025.
  • 25 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top